Compare Sanofi SA (SNY) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Zillow Group Inc Class C — how do they compare? Sanofi SA trades at $43.7 (market cap $104.83B), while Zillow Group Inc Class C trades at $32.8 (market cap $7.54B). The key difference: Sanofi SA is far larger — about 13.9× Zillow Group Inc Class C's market cap, and Sanofi SA pays a 5.5% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals.
| SNY | Z | |
|---|---|---|
Market Cap | $104.83B | $7.54B |
Sector | Health | Media |
52-Week High | $52.34 | $90.35 |
52-Week Low | $41.33 | $29.41 |
Enterprise Value | $121.32B | $7.19B |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
Zillow Group (Z) trades at $33.03, down 2.58% today, amid ongoing class action lawsuits alleging securities fraud between February 2025 and May 2026. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, revenue grew to $2.58B in 2025 with a net income of $23M, yet high P/E of 135.72 reflects premium valuation. Analyst consensus is divided with 46% Buy, 50% Hold, and a $57.67 price target implying significant upside from current levels.
The outlook is clouded by legal risks and volatile cash flows, but improving profitability and analyst targets suggest long-term potential if the company navigates litigation successfully. Key risks include lawsuit outcomes and competitive pressures in real estate tech, while institutional sentiment remains cautiously optimistic given the growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
